This requires Flash to play. Click here to download.

The information on this site is intended for health care professionals
in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Zolinza® [vorinostat] capsules Reactivate Expression
Home About ZOLINZA Efficacy Safety profile Dosage Reimbursement Resource center CTCL overview Prescribing Information Patient Information
Patient Product Information

Clinical phases of CTCL


Patch

Tumor

Plaque

Erythroderma

These photos show the various stages of CTCL: patch, plaque, tumor, and erythroderma.

  • Patch: lesion of any size that does not have significant elevation or induration; may show pigment changes, scaling, crusting, or wrinkling
  • Plaque: lesion of any size that is elevated or indurated; may show pigment changes, scaling, crusting, or follicular prominence
  • Tumor: solid, nodular lesion >1 cm; may be ulcerated
  • Erythroderma: confluent erythematous lesions covering >80% of the body; may or may not include clinically significant blood involvement

Home | Patient Information | Prescribing Information
ZOLINZA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.

20951007(3)-05/09-ZOL
For general information and other services for physicians
MERCK MEDICUSMERCK SOURCEMERCKServices
MerckMedicus, MerckSource, and MerckServices are trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.